Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07136103
PHASE1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
Sponsor: AbbVie
View on ClinicalTrials.gov
Summary
The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.
Official title: A First-in-Human Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-08-19
Completion Date
2026-05
Last Updated
2025-09-02
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ABBV-277
• Intravenous (IV) infusion
DRUG
Placebo
• Intravenous (IV) infusion
Locations (1)
Acpru /Id# 265681
Grayslake, Illinois, United States